A generic version of Tymlos (abaloparatide) has not yet been approved by the U.S. Food and Drug Administration (FDA). DrugPatentWatch.com tracks patent information and potential generic entry dates [1].
When might generic Tymlos become available?
The patent landscape for Tymlos is complex, involving multiple patents related to the drug itself and its methods of use. Information on patent expiry and potential generic entry is continuously updated by resources like DrugPatentWatch.com [1].
What is Tymlos used to treat?
Tymlos is a bone-forming medication approved to treat osteoporosis in postmenopausal women at high risk of fracture [2]. It is administered as a daily injection [3].
How does abaloparatide work?
Abaloparatide is a parathyroid hormone-related peptide (PTHrP) analog. It works by stimulating bone formation, which helps to increase bone mineral density and reduce the risk of fractures [2].
What are the risks associated with Tymlos?
The FDA has issued a boxed warning for Tymlos, highlighting an increased risk of osteosarcoma, a type of bone cancer, observed in animal studies. This risk may be higher with longer use. Tymlos is also contraindicated in patients with Paget's disease of the bone, unexplained elevations of alkaline phosphatase, skeletal metastases, or hyperparathyroidism, and in those who have had radiation therapy affecting the skeleton or bone cancer [2].
How does Tymlos compare to other osteoporosis treatments?
Tymlos is a bone-forming agent, distinct from other osteoporosis treatments that primarily work by slowing bone loss, such as bisphosphonates. It is often used for patients who have not responded well to or cannot tolerate other therapies [2].
Where can I find more information on Tymlos patents and generics?
DrugPatentWatch.com provides detailed information on drug patents, including those for Tymlos, and forecasts potential generic competition dates [1].
---
Sources
1. https://drugpatentwatch.com/
2. Tymlos (abaloparatide) Prescribing Information. Radius Health, Inc.
3. FDA Approves Tymlos (abaloparatide) Injection, a New Bone-Forming Osteoporosis Drug. U.S. Food and Drug Administration.